Investigating how neuraminidase affects blood vessel function in type 2 diabetes
Role of neuraminidase activity on endothelial dysfunction in type 2 diabetes
This study is looking at how a specific enzyme affects blood vessel health in people with type 2 diabetes, aiming to find new ways to help improve blood flow and overall heart health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-10851880 on NIH RePORTER |
What this research studies
This research focuses on understanding how the activity of neuraminidase impacts endothelial dysfunction, which is a key factor in cardiovascular disease among patients with type 2 diabetes. The study aims to explore the mechanisms that lead to impaired flow-mediated dilation (FMD) in blood vessels, a critical measure of endothelial function. By examining the role of the glycocalyx, a protective layer on blood vessels, the researchers hope to identify new therapeutic targets that could improve vascular health in these patients. The approach involves both laboratory experiments and clinical assessments to gather comprehensive data on endothelial function.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with type 2 diabetes who may be experiencing cardiovascular issues.
Not a fit: Patients without type 2 diabetes or those with other unrelated cardiovascular conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve blood vessel function and reduce cardiovascular disease risk in patients with type 2 diabetes.
How similar studies have performed: Previous research has shown promising results in understanding endothelial dysfunction in diabetes, but this specific approach to targeting neuraminidase is relatively novel.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Martinez-Lemus, Luis a — University of Missouri-Columbia
- Study coordinator: Martinez-Lemus, Luis a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.